Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preclinical HCM (identified sarcomere mutation with no clinical evidence of left ventricular hypertrophy)~* Able to provide informed consent (or parental consent)~Exclusion Criteria:~* Contraindication to diltiazem administration~* Impaired hepatic or renal function~* Age \< 5 years~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- I- Diltiazem (Type: EXPERIMENTAL): Diltiazem- study medication
- II- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).